Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response

Cancer Research

Volumn 74, Issue 15, 2014, Pages 4133-4144

  Deng, Jiusheng ^a   Yuan, Shala ^a   Pennati, Andrea ^a   Murphy, Jordan ^a   Wu, Jian Hui ^b   Lawson, David ^a   Galipeau, Jacques ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GIFT4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; STAT PROTEIN; UNCLASSIFIED DRUG; HYBRID PROTEIN; IL4 PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CELL ENGINEERING; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GIFT4 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR GENE; ANIMAL; C57BL MOUSE; CELL GROWTH; CONFOCAL MICROSCOPY; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; PROCEDURES; PROTEIN ENGINEERING;

ANIMALS; B-LYMPHOCYTES; CELL GROWTH PROCESSES; GENETIC ENGINEERING; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-4; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84905508405     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0708     Document Type: Article

References (41)

1. Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006;12:2353s-8s.
2. Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer 2010;10:425-34.
3. Gupta R, Emens LA. GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med 2010;10:52-60.
4. Waller EK. The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist 2007;12 Suppl 2:22-6.
5. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27.
6. Fewkes NM, Mackall CL. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J 2010;16:392-8.
7. Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, et al. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008;26:2034-9.
8. Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 2009;15:2123-9.
9. Sportes C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010;16:727-35.
10. Teague RM, Sather BD, Sacks JA, Huang MZ, Dossett ML, Morimoto J, et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 2006;12:335-41.
11. Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2011;23:286-92.
12. Williams P, Galipeau J. GM-CSF-based fusion cytokines as ligands for immune modulation. J Immunol 2011 May 15;186:5527-32.
13. Rafei M, Hsieh J, Zehntner S, Li M, Forner K, Birman E, et al. A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat Med 2009;15:1038-45.
14. Stagg J, Wu JH, Bouganim N, Galipeau J. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res 2004;64:8795-9.
15. Penafuerte C, Bautista-Lopez N, Boulassel MR, Routy JP, Galipeau J. The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation. Cancer Res 2009;69:9020-8.
16. Williams P, Bouchentouf M, Rafei M, Romieu-Mourez R, Hsieh J, Boivin MN, et al. A dendritic cell population generated by a fusion of GM-CSF and IL-21 induces tumor-antigen-specific immunity. J Immunol 2010;185:7358-66.
17. Williams P, Rafei M, Bouchentouf M, Raven J, Yuan S, Cuerquis J, et al. A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo. Mol Ther 2010;18:1293-301.
18. Gluckman JC, Canque B, Chapuis F, Rosenzwajg M. In vitro generation of human dendritic cells and cell therapy. Cytokines Cell Mol Ther 1997;3:187-96.
19. Vopenkova K, Mollova K, Buresova I, Michalek J. Complex evaluation of humanmonocyte-derived dendritic cells for cancer immunotherapy. J Cell Mol Med 2012;16:2827-37.
20. Rafei M, Deng J, Boivin MN, Williams P, Matulis SM, Yuan S, et al. A MCP1 fusokine with CCR2-specific tumoricidal activity. Mol Cancer 2011;10:121.
21. Li P, Yuan S, Galipeau J. A fusion cytokine coupling GMCSF to IL9 induces heterologous receptor clustering and STAT1 hyperactivation through JAK2 promiscuity. PLoS ONE 2013;8:e69405.
22. Rauch PJ, Chudnovskiy A, Robbins CS, Weber GF, Etzrodt M, Hilgendorf I, et al. Innate response activator B cells protect against microbial sepsis. Science 2012;335:597-601.
23. Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 2010;185:4977-82.
24. Penafuerte C, Ng S, Bautista-Lopez N, Birman E, Forner K, Galipeau J. B effector cells activated by a chimeric protein consisting of IL-2 and the ectodomain of TGF-beta receptor II induce potent antitumor immunity. Cancer Res 2012;72:1210-20.
25. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599-602.
26. Lampropoulou V, Shen P, Hilgenberg E, Ries S, Opitz C, Fillatreau S. Functional interactions between B lymphocytes and the innate immune system. Infect Disord Drug Targets 2012;12:191-9.
27. Anolik JH, Looney RJ, Lund FE, Randall TD, Sanz I. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009;45:144-58.
28. Kim S, Fridlender ZG, Dunn R, Kehry MR, Kapoor V, Blouin A, et al. Bcell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models. J Immunother 2008;31:446-57.
29. Qin Z, Richter G, Schuler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998;4:627-30.
30. Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells on antitumor immunity. Cancer Res 2006;66:7741-7.
31. Chung Y, Kim BS, Kim YJ, Ko HJ, Ko SY, Kim DH, et al. CD1drestricted T cells license B cells to generate long-lasting cytotoxic antitumor immunity in vivo. Cancer Res 2006;66:6843-50.
32. Tomihara K, Shin T, Hurez VJ, Yagita H, Pardoll DM, Zhang B, et al. Aging-associated B7-DC+ B cells enhance anti-tumor immunity via Th1 and Th17 induction. Aging Cell 2012;11:128-38.
33. Miyauchi K, Urano E, Yoshiyama H, Komano J. Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma. Cancer Sci 2011;102:1236-41.
34. Oliveira FL, Aguiar AM, Borojevic R, El-Cheikh MC. IgE expression on the surface of B1 and B2 lymphocytes in experimental murine schistosomiasis. Braz J Med Biol Res 2005;38:1033-42.
35. Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011;121:4746-57.
36. Selleri S, Deola S, Pos Z, Jin P, Worschech A, Slezak SL, et al. GMCSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells. J Transl Med 2008;6:17.
37. Gonzalez-Martin A, Gomez L, Lustgarten J, Mira E, Manes S. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4 (+) and CD8 (+) T cells. Cancer Res 2011;71:5455-66.
38. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997;100:2757-65.
39. Hollsberg P, Batra V, Dressel A, Hafler DA. Induction of anergy in CD8 T cells by B cell presentation of antigen. J Immunol 1996;157:5269-76.
40. Brodie GM, Wallberg M, Santamaria P, Wong FS, Green EA. B-cells promote intra-islet CD8+ cytotoxic T-cell survival to enhance type 1 diabetes. Diabetes 2008;57:909-17.
41. Bennett SR, Carbone FR, Toy T, Miller JF, Heath WR. B cells directly tolerize CD8 (+) T cells. J Exp Med 1998;188:1977-83.